Cargando…

Fluvoxamine for symptomatic outpatients with COVID-19

Detalles Bibliográficos
Autores principales:	Wu, Peter E., Austin, Emily, Leong, Derek
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	CMA Impact Inc. 2022
Materias:	Practice
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8863199/ https://www.ncbi.nlm.nih.gov/pubmed/35045990 http://dx.doi.org/10.1503/cmaj.220011

Ejemplares similares

Fluvoxamine pour les patients atteints de COVID-19 non hospitalisés
por: Wu, Peter E., et al.
Publicado: (2022)

Correspondence on Fluvoxamine Treatment of Patients with Symptomatic COVID-19
por: Sookaromdee, Pathum, et al.
Publicado: (2022)

Reply: Correspondence on Fluvoxamine Treatment of Patients with Symptomatic COVID-19
por: Seo, Hyeonji, et al.
Publicado: (2022)

Fluvoxamine for outpatients with COVID-19: where do we stand?
por: Berwanger, Otavio
Publicado: (2022)

The STOP COVID 2 Study: Fluvoxamine vs Placebo for Outpatients With Symptomatic COVID-19, a Fully Remote Randomized Controlled Trial
por: Reiersen, Angela M, et al.
Publicado: (2023)

Early Fluvoxamine Reduces the Risk for Clinical Deterioration in Symptomatic Outpatients with COVID-19: A Real-World, Retrospective, before–after Analysis
por: Tsiakalos, Aristotelis, et al.
Publicado: (2023)

Fluvoxamine for Outpatient Management of COVID-19 to Prevent Hospitalization: A Systematic Review and Meta-analysis
por: Lee, Todd C., et al.
Publicado: (2022)

Fluvoxamine for the treatment of COVID-19
por: Dodds, Michael G, et al.
Publicado: (2022)

Fluvoxamine for the treatment of COVID-19
por: Boulware, David R, et al.
Publicado: (2022)

Fluvoxamine for the treatment of COVID-19
por: Kim, Hyun, et al.
Publicado: (2022)

Fluvoxamine for the treatment of COVID-19
por: Marzolini, Catia, et al.
Publicado: (2022)

Fluvoxamine, melatonin and COVID-19
por: Anderson, George M.
Publicado: (2021)

Fluvoxamine
por: DeVane, C Lindsay
Publicado: (2005)

Impact of fluvoxamine on outpatient treatment of COVID-19 in Honduras in a prospective observational real-world study
por: Pineda, Estela, et al.
Publicado: (2022)

Fluvoxamine for the treatment of COVID-19 – Author's reply
por: Reis, Gilmar, et al.
Publicado: (2022)

Outpatient treatment of Covid-19 with metformin, ivermectin, and fluvoxamine and the development of Long Covid over 10-month follow-up
por: Bramante, Carolyn T., et al.
Publicado: (2022)

Trial Sequential Analysis and Updated Meta-Analysis of Fluvoxamine on Clinical Deterioration in Adult Patients with Symptomatic COVID-19 Infection
por: Yu, Chia-Ling, et al.
Publicado: (2023)

Old drug fluvoxamine, new hope for COVID-19
por: Hashimoto, Yaeko, et al.
Publicado: (2021)

Overview of the potential use of fluvoxamine for COVID-19 and long COVID
por: Hashimoto, Kenji
Publicado: (2023)

Tecovirimat for monkeypox
por: Halani, Sheliza, et al.
Publicado: (2022)

Fluvoxamine Treatment of Patients with Symptomatic COVID-19 in a Community Treatment Center: A Preliminary Result of Randomized Controlled Trial
por: Seo, Hyeonji, et al.
Publicado: (2022)

Potential Role of the Antidepressants Fluoxetine and Fluvoxamine in the Treatment of COVID-19
por: Mahdi, Mohamed, et al.
Publicado: (2022)

Mechanisms of action of fluvoxamine for COVID-19: a historical review
por: Hashimoto, Yaeko, et al.
Publicado: (2022)

Erratum: Fluvoxamine Treatment of Patients with Symptomatic COVID-19 in a Community Treatment Center: A Preliminary Result of Randomized Controlled Trial
Publicado: (2022)

Fluvoxamine in the treatment of anxiety disorders
por: Irons, Jane
Publicado: (2005)

Repurposing fluvoxamine, and other psychiatric medications, for COVID‐19 and other conditions
por: Lenze, Eric J., et al.
Publicado: (2022)

Why we should not recommend or offer fluvoxamine to COVID-19 patients?
por: Trkulja, Vladimir
Publicado: (2022)

Heme oxygenase agonists—fluvoxamine, melatonin—are efficacious therapy for Covid-19
por: Hooper, Philip L.
Publicado: (2021)

Effectiveness of fluvoxamine at preventing COVID-19 infection from turning severe
por: Boretti, Alberto
Publicado: (2023)

Developing an Outpatient Pediatric Pre-Procedure COVID-19 Testing Model
por: O'Connor, Katherine, et al.
Publicado: (2021)

Fluvoxamine: A Review of Its Mechanism of Action and Its Role in COVID-19
por: Sukhatme, Vikas P., et al.
Publicado: (2021)

A 53-year-old woman with a suspected drug overdose
por: Kobylianskii, Jane, et al.
Publicado: (2022)

Remdesivir for patients with COVID-19
por: Wu, Peter E., et al.
Publicado: (2021)

Tolerability and safety of fluvoxamine and other antidepressants
por: Westenberg, HGM, et al.
Publicado: (2006)

Fluvoxamine alleviates paclitaxel-induced neurotoxicity
por: Tanimukai, Hitoshi, et al.
Publicado: (2015)

A 54-year-old woman with chronic lithium toxicity
por: Kobylianskii, Jane, et al.
Publicado: (2021)

Quality Improvement for Outpatient COVID-19 Infection Control
por: Clay, Jeremy, et al.
Publicado: (2021)

Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19
por: Seftel, David, et al.
Publicado: (2021)

Resumption of respiratory outpatient services in the COVID-19 era: Experience from Southern Italy
por: Crimi, Claudia, et al.
Publicado: (2020)

There is no reasonable evidence to support efficacy of fluvoxamine in prevention of disease deterioration in COVID-19 outpatients: A comment on two recent meta-analyses advocating its use
por: Trkulja, Vladimir
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_af2n8vvbnbh7v35jrh0kka7sbl